The Core Story: Medexus Pharmaceutical (MDP.T) just grows and grows

Continuing out Core Story program, today’s exploration is a company we just can’t get enough of, Medexus Pharmaceuticals (MDP.T).

CEO Ken D’Entremont has nailed his milestones the last 18 months, continued running revenues up, kept expenses low, and restructured convertible debt to remain in control os his company’s direction going forward.

They’ve blasted through a 2022 short report that shook the stock and the stock price the last three months has jumped significantly, from $1.120 to $3+.

Dig in.

— FULL DISCLOSURE: No longer a client, but we remain shareholders.